Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612000340831
Ethics application status
Not yet submitted
Date submitted
22/03/2012
Date registered
23/03/2012
Date last updated
23/03/2012
Type of registration
Prospectively registered
Titles & IDs
Public title
Can pre-operative Ivabradine and/or Atorvastatin prevent heart injury following surgery for neck of femur fracture in elderly patients?
Query!
Scientific title
A randomised controlled trial of Ivabradine and Atorvastatin in emergent orthopaedic lower limb surgery for neck of femur fracture in elderly patients: a mechanistic study of peri-operative myocardial injury and its prevention using computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism
Query!
Secondary ID [1]
280187
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1129-3244
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary artery disease
286116
0
Query!
Fractures
286117
0
Query!
Peri-operative myocardial injury
286118
0
Query!
Condition category
Condition code
Surgery
286312
286312
0
0
Query!
Other surgery
Query!
Cardiovascular
286340
286340
0
0
Query!
Coronary heart disease
Query!
Injuries and Accidents
286341
286341
0
0
Query!
Fractures
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Patients will be randomised using a computerised block randomisation method with blocks of variable sizes to ensure ‘true’ randomisation and equal numbers in each treatment group. Patients will be randomized to one of four groups in a 1:1:1:1 ratio.
1) No treatment (control group)
2) Atorvastatin orally 80 mg daily till discharge from acute hospital care (to home / rehab)
3) Ivabradine 5mg orally twice daily till discharge from acute hospital care (to home / rehab)
4) Ivabradine 5 mg orally twice daily and atorvastatin orally 80 mg daily till discharge from acute hospital care (to home / rehab)
Treatment would start on randomization prior to surgery which would be as soon as practicable after admission.
Query!
Intervention code [1]
284511
0
Prevention
Query!
Intervention code [2]
284512
0
Treatment: Drugs
Query!
Comparator / control treatment
No treatment
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
286783
0
The frequency (binary outcome) and magnitude (continuous variable) of new myocardial injury following emergent orthopaedic surgery for lower limb fracture as assessed by troponin I, on a per protocol basis.
Query!
Assessment method [1]
286783
0
Query!
Timepoint [1]
286783
0
Day 0
Day 1
Day 2
Day 3
Query!
Secondary outcome [1]
296644
0
Myocardial infarction according to the universal definition
Query!
Assessment method [1]
296644
0
Query!
Timepoint [1]
296644
0
Day 3
Query!
Secondary outcome [2]
296645
0
Mean HR over 48 hours Holter monitoring postoperatively
Query!
Assessment method [2]
296645
0
Query!
Timepoint [2]
296645
0
48 hours
Query!
Secondary outcome [3]
296646
0
Incidence and duration of AF over 48 Holter monitoring postoperatively
Query!
Assessment method [3]
296646
0
Query!
Timepoint [3]
296646
0
48 hours
Query!
Secondary outcome [4]
296647
0
Serum assays of NT-proBNP, MR-proANP, MR-proADM and CT-proET-1. Samples would be stored at negative 80 degrees prior to testing at external laboratory.
Query!
Assessment method [4]
296647
0
Query!
Timepoint [4]
296647
0
Days 0,1,2,3
Query!
Secondary outcome [5]
296648
0
Serum assays of sPLA2 and Lp-PLA2 mass and activity
Query!
Assessment method [5]
296648
0
Query!
Timepoint [5]
296648
0
Days 0,1
Query!
Secondary outcome [6]
296649
0
Platelet activation as measured by VerifyNow P2Y12 assay.
Query!
Assessment method [6]
296649
0
Query!
Timepoint [6]
296649
0
Preoperative (day 0)
Query!
Secondary outcome [7]
296650
0
Death
Query!
Assessment method [7]
296650
0
Query!
Timepoint [7]
296650
0
In hospital
30 days
12 months
Query!
Secondary outcome [8]
296651
0
Stroke
Query!
Assessment method [8]
296651
0
Query!
Timepoint [8]
296651
0
In hospital
30 days
12 months
Query!
Secondary outcome [9]
296652
0
Symptomatic bradycardia or heart block requiring cessation of ivabradine
Query!
Assessment method [9]
296652
0
Query!
Timepoint [9]
296652
0
In hospital
Query!
Secondary outcome [10]
296653
0
Liver enzyme elevation > 3 times the upper limits of normal
Query!
Assessment method [10]
296653
0
Query!
Timepoint [10]
296653
0
In Hospital
Query!
Eligibility
Key inclusion criteria
1) Age greater than 60 years
2) Neck of femur fracture with planned surgical treatment within 48 hours
Query!
Minimum age
60
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1) Current ivabradine use
2) Patients who do not undergo surgical treatment for lower limb fracture for any reason. If such patients were initially enrolled they will be excluded from the analysis, i.e per protocol analysis.
3) Heart rate < 65bpm prior to randomisation
4) Known liver disease or liver enzymes > 3 times the higher limits of normal
5) Pre-operative troponin elevation
6) Artificial pacemakers, sick sinus syndrome or complete heart block
7) Concomittant CYP3A4 inhibitors – ketoconazole, macrolides, cyclosporin, gestodene, antiretrovirals
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients will be randomised using a computerised block randomisation method with blocks of variable sizes to ensure ‘true’ randomisation and equal numbers in each treatment group using sealed opaque envelopes. Patients will be randomized to one of four groups in a 1:1:1:1 ratio
1) No treatment (control group)
2) Atorvastatin 80 mg daily
3) Ivabradine twice daily (as per protocol)
4) Ivabradine twice daily (as per protocol) and atorvastatin 80 mg daily
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computerised block randomisation method with blocks of variable sizes to ensure ‘true’ randomisation and equal numbers in each treatment group using sealed opaque envelopes.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Factorial
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
15/04/2012
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
284936
0
Hospital
Query!
Name [1]
284936
0
Northern hospital
Query!
Address [1]
284936
0
185 Cooper Street
Epping Vic 3076
Query!
Country [1]
284936
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Northern hospital
Query!
Address
Cardiology Department
The Northern hospital
185 Cooper Street
Epping vic 3076
Query!
Country
Australia
Query!
Secondary sponsor category [1]
283822
0
None
Query!
Name [1]
283822
0
Query!
Address [1]
283822
0
Query!
Country [1]
283822
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
286945
0
The Northern Health Ethics Committee
Query!
Ethics committee address [1]
286945
0
185 Cooper street Epping Vic 3076
Query!
Ethics committee country [1]
286945
0
Australia
Query!
Date submitted for ethics approval [1]
286945
0
27/03/2011
Query!
Approval date [1]
286945
0
Query!
Ethics approval number [1]
286945
0
Query!
Summary
Brief summary
In patients undergoing urgent orthopaedic surgery , Heart muscle damage around the time of surgery(perioperative myocardial Injury-PMI) can occure in 52.9% of patients shown in a study conducted in the northern hospital. The majority of these patients were asymptomatic, with only 9.8% of patients meeting the universal definition criteria for myocardial infarction (heart attack). One year mortality was dramatically increased across the board in those with any troponin(a blood test showing heart muscle damage) elevation (37% versus 2.1%)after the surgery. The exact mechanisms of PMI are not well understood, however two broad theories are postulated; myocardial(heart muscle) stress and cholestrol plaque rupture. Prevention of myocardial stress and/or plaque rupture may reduce the incidence of PMI and have been the subject of multiple studies. This study is going to assess if Ivabradine(a medication lowers the heart rate without affecting the blood pressure) will reduce the rate and magnitude of PMI following emergent lower limb orthopaedic surgery by reducing heart rate and attenuating catecholamine(stress hormons) induced tachycardia(fast heart rate) after operation and to assess if it will correlate with a reduction in biomarkers of cardiovascular stress(blood tests) as measured by NT-proBNP, MR-proANP, MR-proADM and CT-proET-1 and if it will reduce the incidence and burden of atrial fibrillation after the surgery. Also this study is going to assess if Atorvastatin(a medication lowers the cholestrol and inflamatiom) will reduce the rate and magnitude of PMI following emergent lower limb orthopaedic surgery and if it will correlate with a reduction in sPLA2 and Lp-PLA2 mass and activity(markers of cholesterol plaque burden and inflammation ). Also we will assess if that patients with higher measures of platelet function(aggregation and reactivity) before and after surgery will have an increased incidence and magnitude of PMI and if patients with a higher burden of atherosclerotic(chorestrol plaque) disease as measured by CT coronary calcium scores( a ct scan messuring amount of calcium in arteries supplying blood to the heart) will have a higher incidence and magnitidue of PMI. And finally to assess if that the benefit from reduction in the incidence and magnitude of PMI by Ivabradine and Atorvastatin is derived primarily in patients with greater atherosclerotic (cholesterol Plaque) burden as measured by higher CT coronary calcium scores.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33954
0
Query!
Address
33954
0
Query!
Country
33954
0
Query!
Phone
33954
0
Query!
Fax
33954
0
Query!
Email
33954
0
Query!
Contact person for public queries
Name
17201
0
A/Prof William Van Gaal
Query!
Address
17201
0
Director of Cardiology
Northern hospital
185 Cooper Street
Epping Vic 3076
Query!
Country
17201
0
Australia
Query!
Phone
17201
0
+61384058154
Query!
Fax
17201
0
+61384058405
Query!
Email
17201
0
[email protected]
Query!
Contact person for scientific queries
Name
8129
0
A/Prof William Van Gaal
Query!
Address
8129
0
Director of Cardiology
Northern hospital
185 Cooper Street
Epping Vic 3076
Query!
Country
8129
0
Australia
Query!
Phone
8129
0
+61384058154
Query!
Fax
8129
0
+61384058405
Query!
Email
8129
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF